Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00006208
- Locations
- 🇺🇸
East Bay Clinical Trial Ctr, Concord, California, United States
🇺🇸Orange Coast Med Group, Newport Beach, California, United States
🇺🇸Health Positive, Safety Harbor, Florida, United States
Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 400
- Registration Number
- NCT00011895
- Locations
- 🇺🇸
Therapeutic Concepts, Houston, Texas, United States
🇺🇸Diversified Med Practices, PA, Houston, Texas, United States
🇺🇸Infectious Diseases Associates of Houston, Houston, Texas, United States
The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 80
- Registration Number
- NCT00002213
- Locations
- 🇺🇸
Niaid / Nih, Bethesda, Maryland, United States
🇺🇸Northwestern Univ Med School AIDS Treatment Unit, Chicago, Illinois, United States
🇺🇸Univ Int Med Assoc Inc / Holmes Hosp / U of Cincinnati, Cincinnati, Ohio, United States
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 150
- Registration Number
- NCT00005018
- Locations
- 🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸Altamed Medical Health Services, Los Angeles, California, United States
🇺🇸Gary Richmond MD, Fort Lauderdale, Florida, United States
Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Agouron Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00005000
- Locations
- 🇺🇸
Agouron Pharmaceuticals Inc, San Diego, California, United States
The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00002387
- Locations
- 🇺🇸
San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸Brown Univ / Miriam Hosp, Providence, Rhode Island, United States
🇺🇸Rush Med Ctr / Section of Infectious Diseases, Chicago, Illinois, United States
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00004852
- Locations
- 🇺🇸
Univ of Texas / Med School at Houston, Houston, Texas, United States
🇺🇸Harbor - UCLA Med Ctr, Torrance, California, United States
🇺🇸Bach and Godofsky, Bradenton, Florida, United States
A Study of Indinavir Taken With or Without DMP 266
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Target Recruit Count
- 300
- Registration Number
- NCT00002393
- Locations
- 🇺🇸
Tulane Univ / Tulane / LSU Clinical Trials Unit, New Orleans, Louisiana, United States
🇺🇸Vanderbilt Univ, Nashville, Tennessee, United States
🇺🇸Chicago Ctr for Clinical Research, Chicago, Illinois, United States
A Study to Compare Two Anti-HIV Drug Combinations
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 146
- Registration Number
- NCT00002447
- Locations
- 🇺🇸
UCSF - San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸Saint Michael's Med Ctr / Dept of Infectious Diseases, Newark, New Jersey, United States
🇺🇸Associates in Research, Fort Myers, Florida, United States
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
- Conditions
- HIV Infections
- Locations
- 🇺🇸
ViRx Inc, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.